COMP <GO>
NBIX vs JNJ // FREE CASH FLOW YIELD
Neurocrine Biosciences Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NBIX 6
— JNJ 8
▲ FREE CASH FLOW YIELD LEADER: NBIX
LAST: $146.10 (-0.19%) • MKT CAP: $14.88B
fcf-yield
5.03%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NBIX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NBIX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 67.90% | +28.10 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.70% | 25.50% | -9.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.8x | 18.5x | +4.30 | JNJ | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 5.03% | 2.97% | +2.06 | NBIX | /fcf-yield <GO> |
| Operating Margin | 21.60% | 34.70% | -13.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 16.70% | 28.50% | -11.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 21.40% | 6.00% | +15.40 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.13 | 5.59 | +2.54 | NBIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.20% | +0.10 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.5 | 60.4 | -4.89 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 1.08 | +0.05 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.1x | 23.0x | +3.10 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.88B | $662.49B | -$647.61B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NBIX REV | JNJ REV | NBIX GROSS % | JNJ GROSS % | NBIX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $94.19B | 98.2% | 67.9% | $748.7M | $19.70B |
| FY 2024 | $2.36B | $88.82B | 98.6% | 69.1% | $557.2M | $19.84B |
| FY 2023 | $1.89B | $85.16B | 44.0% | 44.0% | $305.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NBIX // BETA 1.13
JNJ // BETA 1.08